| CASE REPORT |
|
| Year : 2021 | Volume
: 7
| Issue : 2 | Page : 84-87 |
|
|
Lenalidomide in a case of thalidomide intolerant erythema nodosum leprosum
Shankar Lal Chahar, Sidharth Mani, Jandhyala Sridhar, Padmapriya Srinivasan
Department of Dermatology, INHS Asvini, Mumbai, Maharashtra, India
Correspondence Address:
Jandhyala Sridhar
Department of Dermatology, INHS Asvini, Colaba, Mumbai 400005, Maharashtra.
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijdd.ijdd_50_20
|
|
|
Lenalidomide is an immunomodulatory drug, which is considered to be a derivative of thalidomide. It has a more potent suppressive effect on tumor necrosis factor-α (TNF-α) production and has a more tolerable adverse effect profile as compared to its parent drug. It has been approved by FDA for use in multiple hematopoietic malignancies and myelodysplasia, but unlike thalidomide its use in erythema nodosum leprosum (ENL) has not been reported so far. Herein we report a case of 45-year-old man with Hansen’s disease (BL) on MDT for 4 months who presented with ENL and was managed with minimum dose of lenalidomide. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
